Announcements - OBI Pharma 台灣浩鼎

2021.May.05

OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned

2021.Apr.29

Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company's Board of Directors resolved to convene the 2021 Annual General Shareholders' Meeting

2021.Apr.29

Announcement of the resolution by the Board of Directors not to distribute dividends by the company, on behalf of major subsidiary Amaran Biotechnology, Inc.

2021.Apr.21

OBI-3424 completes its phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to phase 2 as planned

2021.Apr.20

OBI Filed the Application of Phase III Human Clinical Study for the Active Cancer Immunotherapy OBI-822, Adagloxad Simolenin, to the Health Authority of Peru

2021.Apr.07

OBI’s application to initiate the Phase III clinical study of the active cancer immunotherapy OBI-822 (Adagloxad Simolenin) has been denied by the Ministry of Health, Argentina

2021.Mar.17

OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland

2021.Mar.12

The Board of Directors resolved to hold 2021 Annual General Meeting

2021.Mar.12

Announcement of not Distributing Dividends in 2020

2021.Mar.12

Announcement of 2020 Consolidated Financial Report

News

Latest News

Events

Latest events